Abstract

Hesitations for clinicians in adopting DRG stimulation for pain, in contrast to steroid injections, include fears surrounding high technical difficulty of lead placement and patient safety - while balancing potential patient benefit 1,2. Furthermore, DRG trial leads are percutaneous and present infection paths requiring short-term use. Here we present the placement of a fully implantable DRG trial lead, the Injectrode, using the clinically familiar transforaminal approach, with acute efficacy assessed in a preclinical model.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call